Skip to main content
    O

    OPTIMIZERx Corp (OPRX)

    Official site

    HEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ

    $6.64
    -0.70 (-9.54%)

    Market Cap: $138.26M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    OPTIMIZERx Corp (OPRX) Earnings: Report Dates and Results

    Updated Nov 11, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    OPTIMIZERx (OPRX) is expected to report earnings on Mar 3, 2027. In the quarter ended Sep 30, 2026, OPTIMIZERx reported EPS of $0.13, above the $0.07 estimate. It beat the EPS estimate in each of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    64%(23/36)
    Avg Surprise
    +69.11%
    Streak
    9 Q

    Upcoming Estimates

    Reports Mar 3, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.40
    Range$0.30 - $0.58
    8 analysts
    Revenue Consensus
    $31.58M
    Range$24.54M - $38.33M
    8 analysts

    Next Report

    OPRX has an expected report date of Mar 3, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 21.6% below the $0.51 reported for the quarter ended Dec 31, 2025.

    OPRX Earnings Call

    The latest OPRX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 36 quarters below that had an estimate, OPRX beat 23, missed 9 and matched 4. Revenue for the quarter ended Sep 30, 2026 was $21.61M, down 17.1% from $26.07M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.13$0.07N/A+85.71%Beat-35.0%50 up, 1 downNov 11, 2026$21.61M
    Jun 30, 2026$0.08$0.01N/A+700.00%Beat-50.0%50 up, 1 downAug 12, 2026$20.50M
    Mar 31, 2026Not reported$0.03-$0.06 - $0.04N/ANot reportedN/A61 up, 1 downMay 12, 2026$19.84M
    Dec 31, 2025$0.51$0.22$0.19 - $0.25+131.82%Beat+264.3%70 up, 2 downMar 5, 2026$32.24M
    Sep 30, 2025$0.20$0.04$0.00 - $0.12+400.00%Beat+66.7%71 up, 0 downNov 6, 2025$26.07M
    Jun 30, 2025$0.16-$0.09N/A+277.78%Beat+700.0%76 up, 1 downAug 7, 2025$29.20M
    Mar 31, 2025$0.08-$0.12-$0.18 - -$0.04+166.67%BeatN/A70 up, 5 downMay 12, 2025$21.93M
    Dec 31, 2024$0.14$0.10N/A+40.00%Beat-46.2%82 up, 0 downMar 12, 2025$32.32M
    Sep 30, 2024$0.12$0.06$0.01 - $0.10+100.00%Beat+33.3%70 up, 0 downNov 13, 2024$21.31M
    Jun 30, 2024$0.02-$0.07-$0.09 - $0.00+128.57%BeatN/A60 up, 0 downAug 8, 2024$18.81M
    Mar 31, 2024-$0.11-$0.10-$0.25 - -$0.03-10.00%MissN/A62 up, 0 downMay 14, 2024$19.69M
    Dec 31, 2023$0.26$0.32$0.23 - $0.53-18.75%Miss+4.0%62 up, 0 downMar 28, 2024$28.37M
    Sep 30, 2023$0.09$0.04-$0.03 - $0.05+125.00%Beat+28.6%63 up, 0 downNov 6, 2023$16.33M
    Jun 30, 2023-$0.01-$0.02-$0.04 - $0.00+50.00%Beat-125.0%70 up, 0 downAug 14, 2023$13.82M
    Mar 31, 2023-$0.09-$0.08-$0.11 - -$0.04-12.50%MissN/A70 up, 1 downMay 10, 2023$13.00M
    Dec 31, 2022$0.25$0.24$0.20 - $0.28+4.17%Beat+13.6%70 up, 0 downMar 8, 2023$19.65M
    Sep 30, 2022$0.07$0.04$0.01 - $0.06+75.00%Beat-22.2%70 up, 0 downNov 8, 2022$15.09M
    Jun 30, 2022$0.04$0.09N/A-55.56%Miss-60.0%N/A0 up, 0 downAug 9, 2022$13.98M
    Mar 31, 2022-$0.01-$0.01-$0.06 - $0.050.00%In line-133.3%50 up, 1 downMay 4, 2022$13.73M
    Dec 31, 2021$0.22$0.21$0.17 - $0.22+4.76%Beat+37.5%53 up, 0 downFeb 24, 2022$20.31M
    Sep 30, 2021$0.09$0.13$0.12 - $0.15-30.77%Miss+50.0%40 up, 0 downNov 9, 2021$16.12M
    Jun 30, 2021$0.10$0.07$0.06 - $0.08+42.86%Beat+400.0%5N/AAug 4, 2021$13.63M
    Mar 31, 2021$0.03$0.01-$0.02 - $0.03+200.00%BeatN/A5N/AMay 6, 2021$11.23M
    Dec 31, 2020$0.16$0.16$0.13 - $0.190.00%In lineN/A4N/AFeb 24, 2021$16.43M
    Sep 30, 2020$0.06$0.04$0.03 - $0.05+50.00%BeatN/A4N/ANov 9, 2020$10.52M
    Jun 30, 2020$0.02-$0.03-$0.06 - -$0.02+166.67%Beat-77.8%4N/AAug 5, 2020$8.78M
    Mar 31, 2020-$0.06-$0.03-$0.07 - $0.00-100.00%Miss-200.0%4N/AMay 4, 2020$7.58M
    Dec 31, 2019-$0.03$0.01-$0.03 - $0.03-400.00%MissN/A4N/AFeb 27, 2020$7.38M
    Sep 30, 2019-$0.05$0.08$0.05 - $0.10-162.50%Miss-171.4%4N/ANov 5, 2019$5.00M
    Jun 30, 2019$0.09$0.08$0.06 - $0.10+12.50%Beat+28.6%4N/AAug 7, 2019$7.01M
    Mar 31, 2019$0.06$0.02N/A+200.00%Beat+100.0%3N/AMay 8, 2019$5.21M
    Dec 31, 2018-$0.01-$0.01-$0.03 - $0.000.00%In lineN/A4N/AFeb 26, 2019$6.58M
    Sep 30, 2018$0.07$0.06N/A+16.67%BeatN/A3N/ANov 5, 2018$5.42M
    Jun 30, 2018$0.07$0.03N/A+133.33%BeatN/A3N/AAug 7, 2018$5.10M
    Mar 31, 2018$0.03-$0.03N/A+200.00%BeatN/A1N/AMay 2, 2018$4.11M
    Dec 31, 2017-$0.03-$0.03N/A0.00%In lineN/AN/AN/AFeb 27, 2018$2.52M
    Sep 30, 2017-$0.04-$0.03N/A-33.33%MissN/AN/AN/ANov 2, 2017$1.40M
    Jun 30, 2017-$0.04N/AN/AN/AN/AN/AN/AN/AAug 1, 2017$1.26M
    Mar 31, 2017-$0.03N/AN/AN/AN/AN/AN/AN/AMay 3, 2017$770340
    Dec 31, 2016-$0.02N/AN/AN/AN/AN/AN/AN/AMar 8, 2017$527330
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $0.95, up 458.8% from the year before. It was -$0.10 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$0.95+458.8%
    Dec 31, 2024$0.17-32.0%
    Dec 31, 2023$0.25-28.6%
    Dec 31, 2022$0.35-20.5%
    Dec 31, 2021$0.44+144.4%
    Dec 31, 2020$0.18+157.1%
    Dec 31, 2019$0.07-56.3%
    Dec 31, 2018$0.16N/A
    Dec 31, 2017-$0.14N/A
    Dec 31, 2016-$0.10N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,700 words across 9 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,7289
    2026Q2Jun 30, 20265,9767
    2026Q1Mar 31, 20264,8337
    2025Q4Dec 31, 20256,3019
    2025Q3Sep 30, 20255,15110
    2025Q2Jun 30, 20254,8569
    2025Q1Mar 31, 20255,30310
    2024Q4Dec 31, 20246,10711

    2026Q3 Earnings Call

    Opening remarks

    Stephen Silvestro CEO Thank you, operator, and good afternoon, everyone. Thank you for joining our third quarter 2026 earnings call. We're pleased to report third quarter revenue of $21.6 million and adjusted EBITDA of $6.3 million, both of which exceeded consensus expectations. While revenue came in modestly ahead of expectations, our adjusted EBITDA performance was again particularly strong, reflecting our continued gross margin strength and the benefits of our disciplined approach to cost management. Importantly, our bottom line performance reflects the structural improvements we have made to our operating model, including the cost reduction initiative completed during the first half of the year. These actions have allowed us to operate more efficiently while continuing to invest in the technologies, products and commercial capabilities we believe will drive long-term growth. Although the broader pharmaceutical marketing environment remains dynamic, we believe our third quarter performance demonstrates the underlying profitability and operating leverage of our business. At the same time, we recognize that our top line performance has not yet reflected the full potential of investments we've made in our platform. Contracted revenue for 2026 continues to track approximately 20% below the comparable prior year. As a result, we have a larger amount of revenue to secure and recognize during the fourth quarter to achieve our previously issued guidance. Given this backdrop, we are updating the full year '26 revenue guidance to a range of $87 million to $93 million, while maintaining our adjusted EBITDA guidance of $21 million to $25 million. This revision reflects expected timing of our customer spending decisions and the increased amount of business that would need to convert and be recognized before year-end to achieve our previous revenue expectations. We remain encouraged by the sustainable progress we're making across our business, including a very encouraging start to 2027. We are seeing expanded opportunities within key accounts, indications of pent-up demand as customers ramp up the 2027 RFP season and growing commercial opportunities associated with our programmatic distribution capabilities. We are also pleased to report that one of our previously displaced top 5 clients has returned and begun to reinvest in new solutions with OptimizeRx. As you may recall, this customer represented a meaningful portion of our revenue in 2025, but had not generated revenue during the first 3 quarters of 2026. We are now pleased to report that we have begun generating revenue from this customer during the fourth quarter. While spending has not yet returned to historical levels, we view this as a positive development and an encouraging indication of renewed customer engagement and interest and contribution to growth next year in 2027. In addition, we're encouraged by the progress we've made by strengthening our commercial organization.

    Frequently Asked Questions About OPRX

    When is OPTIMIZERx's next earnings date?

    OPTIMIZERx's next earnings report is expected for Mar 3, 2027.

    Did OPRX beat earnings estimates last quarter?

    Yes. OPTIMIZERx reported EPS of $0.13 for the quarter ended Sep 30, 2026, above the $0.07 estimate, a 85.71% surprise.

    What EPS do analysts expect from OPRX next quarter?

    The consensus EPS estimate for OPTIMIZERx for the quarter ending Dec 31, 2026 is $0.40 from 8 analysts, with estimates from $0.30 to $0.58.

    How often does OPRX beat earnings estimates?

    OPTIMIZERx beat the EPS estimate in each of the 8 most recent quarters that had an estimate, with an average surprise of +237.75%.